ATP-binding cassette transporters in progression and clinical outcome of pancreatic cancer: What is the way forward?
- PMID: 30090003
- PMCID: PMC6079284
- DOI: 10.3748/wjg.v24.i29.3222
ATP-binding cassette transporters in progression and clinical outcome of pancreatic cancer: What is the way forward?
Abstract
Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive diseases and is characterized by high chemoresistance, leading to the lack of effective therapeutic approaches and grim prognosis. Despite increasing understanding of the mechanisms of chemoresistance in cancer and the role of ATP-binding cassette (ABC) transporters in this resistance, the therapeutic potential of their pharmacological inhibition has not been successfully exploited yet. In spite of the discovery of potent pharmacological modulators of ABC transporters, the results obtained in clinical trials have been so far disappointing, with high toxicity levels impairing their successful administration to the patients. Critically, although ABC transporters have been mostly studied for their involvement in development of multidrug resistance (MDR), in recent years the contribution of ABC transporters to cancer initiation and progression has emerged as an important area of research, the understanding of which could significantly influence the development of more specific and efficient therapies. In this review, we explore the role of ABC transporters in the development and progression of malignancies, with focus on PDAC. Their established involvement in development of MDR will be also presented. Moreover, an emerging role for ABC transporters as prognostic tools for patients' survival will be discussed, demonstrating the therapeutic potential of ABC transporters in cancer therapy.
Keywords: ATP-binding cassette transporters; Multi-drug resistance; Pancreatic ductal adenocarcinoma; Pancreatic ductal adenocarcinoma prognosis; Predictive markers; Targeted therapies.
Conflict of interest statement
Conflict-of-interest statement: No potential conflicts of interest.
Figures


Similar articles
-
LAMC2 promotes cancer progression and gemcitabine resistance through modulation of EMT and ATP-binding cassette transporters in pancreatic ductal adenocarcinoma.Carcinogenesis. 2021 Apr 30;42(4):546-556. doi: 10.1093/carcin/bgab011. Carcinogenesis. 2021. PMID: 33624791 Free PMC article.
-
The role of non-coding RNAs in ABC transporters regulation and their clinical implications of multidrug resistance in cancer.Expert Opin Drug Metab Toxicol. 2021 Mar;17(3):291-306. doi: 10.1080/17425255.2021.1887139. Epub 2021 Feb 22. Expert Opin Drug Metab Toxicol. 2021. PMID: 33544643 Review.
-
Breast cancer resistance protein expression is associated with early recurrence and decreased survival in resectable pancreatic cancer patients.Pathol Int. 2012 Mar;62(3):167-75. doi: 10.1111/j.1440-1827.2011.02772.x. Epub 2012 Feb 6. Pathol Int. 2012. PMID: 22360504
-
Targeting ABC transporters in PDAC - past, present, or future?Oncotarget. 2024 Jun 20;15:403-406. doi: 10.18632/oncotarget.28597. Oncotarget. 2024. PMID: 38900606 Free PMC article. No abstract available.
-
Mechanisms of drug resistance of pancreatic ductal adenocarcinoma at different levels.Biosci Rep. 2020 Jul 31;40(7):BSR20200401. doi: 10.1042/BSR20200401. Biosci Rep. 2020. PMID: 32677676 Free PMC article. Review.
Cited by
-
Resistance to Gemcitabine in Pancreatic Ductal Adenocarcinoma: A Physiopathologic and Pharmacologic Review.Cancers (Basel). 2022 May 18;14(10):2486. doi: 10.3390/cancers14102486. Cancers (Basel). 2022. PMID: 35626089 Free PMC article. Review.
-
Alteration in the expression of the chemotherapy resistance‑related genes in response to chronic and acute hypoxia in pancreatic cancer.Biomed Rep. 2023 Oct 4;19(6):88. doi: 10.3892/br.2023.1670. eCollection 2023 Dec. Biomed Rep. 2023. PMID: 37901880 Free PMC article.
-
Nanomedicine to Overcome Multidrug Resistance Mechanisms in Colon and Pancreatic Cancer: Recent Progress.Cancers (Basel). 2021 Apr 24;13(9):2058. doi: 10.3390/cancers13092058. Cancers (Basel). 2021. PMID: 33923200 Free PMC article. Review.
-
Natural Phaeosphaeride A Derivatives Overcome Drug Resistance of Tumor Cells and Modulate Signaling Pathways.Pharmaceuticals (Basel). 2022 Mar 24;15(4):395. doi: 10.3390/ph15040395. Pharmaceuticals (Basel). 2022. PMID: 35455394 Free PMC article.
-
Coix Seed Extract Enhances the Anti-Pancreatic Cancer Efficacy of Gemcitabine through Regulating ABCB1- and ABCG2-Mediated Drug Efflux: A Bioluminescent Pharmacokinetic and Pharmacodynamic Study.Int J Mol Sci. 2019 Oct 23;20(21):5250. doi: 10.3390/ijms20215250. Int J Mol Sci. 2019. PMID: 31652737 Free PMC article.
References
-
- ASCO. org CN. Pancreatic Cancer: Statistics. Available from: https://www.cancer.net/cancer-types/pancreatic-cancer/statistics.
-
- Garrido-Laguna I, Hidalgo M. Pancreatic cancer: from state-of-the-art treatments to promising novel therapies. Nat Rev Clin Oncol. 2015;12:319–334. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases